| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 24,832 | 14,064 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 10,756 | -11,092 |
| Cash and cash equivalents at beginning of period | 86,202 | - |
| Cash and cash equivalents at end of period | 96,958 | - |
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)